Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy
Title:
Validation of the NCCN prostate cancer favorable- and unfavorable-intermediate risk groups among men treated with I-125 low dose rate brachytherapy monotherapy
Author:
Tom, Martin C. Reddy, Chandana A. Smile, Timothy D. Zhang, Ryan X. Ciezki, Jay P. Stephans, Kevin L. Mian, Omar Y. Klein, Eric A. Campbell, Steven Ulchaker, James Angermeier, Kenneth Tendulkar, Rahul D.